Acute Asthma - Part 2: When it Starts Winning
Rescue therapies, ventilation strategy, and preventing the spiral into respiratory failure
Asthma rarely fails suddenly. It fails progressively—and then all at once.
The patient who looked “tight but stable” an hour ago is now:
Exhausted
Silent
Hypercapneic
And the physiology has shifted.
This is no longer about broncho-dilation.
This is about ventilation, mechanics, and survival.
In severe asthma, the danger is not hypoxia—it is failure to ventilate.
Recognising the Turn: When Compensated Becomes Pre-terminal
Early asthma is loud.
Severe asthma is often quiet.
Red flags of impending respiratory failure:
Rising or normal PaCO₂
Exhaustion / reduced respiratory effort
Altered mentation
Silent chest
Bradycardia (late)
A normal PaCO₂ in acute asthma is not reassuring—it is a warning of imminent collapse (Cahill et al., 2025).
What is happening physiologically?
Airflow obstruction worsens
Expiratory time becomes insufficient
Dynamic hyperinflation increases
Intra-thoracic pressure rises
Venous return falls
Cardiac output drops
(Mein & Ferrera, 2025)
‘The patient is not tiring because they are hypoxic—they are tiring because they cannot exhale.’
Adjuncts and Escalation: What Actually Works
Once initial therapy fails, escalation must be targeted—not reflexive.
Ketamine in Acute Asthma:
Rescue Bronchodilator, Not Routine Therapy
Ketamine occupies a unique space in acute asthma—pharmacologically appealing, clinically inconsistent, and often used when options are running out.
Where does Ketamine fit?
Ketamine is best understood as a rescue therapy in refractory status asthmaticus—not as routine ED treatment.
It is typically considered when:
Severe asthma persists despite maximal inhaled therapy + steroids ± magnesium
The patient is deteriorating toward intubation
Or as the induction agent of choice during RSI
(Goyal & Agrawal, 2013; La Via et al., 2022)
Mechanism: Why it makes sense
Ketamine produces broncho-dilation through multiple pathways:
NMDA receptor antagonism
Increased endogenous catecholamines → β₂ stimulation
Reduced vagal tone
Direct smooth muscle relaxation
(Goyal & Agrawal, 2013; La Via et al., 2022)
It also demonstrates:
Anti-inflammatory effects
Reduction in airway hyperresponsiveness (experimental data)
(Xiao et al., 2022)
Dosing (acute care context)
Induction (RSI):
1–2 mg/kg IV
Infusion (refractory cases):
0.5–2 mg/kg/hour
(Ueoka et al., 2021; Goyal & Agrawal, 2013)
What does the evidence say?
Despite strong physiological rationale:
Systematic reviews show no consistent benefit in ED patients
RCTs demonstrate minimal or no improvement over standard therapy
Meta-analysis shows non-significant improvement in PEF
(La Via et al., 2022; Alshehri et al., 2022)
In contrast:
ICU case series in life-threatening status asthmaticus report:
Improved pH and PaCO₂
Reduced airway pressures
Facilitation of ventilator weaning
(Heshmati et al., 2003; Ueoka et al., 2021)
Adverse effects
Hallucinations / dysphoria
Increased secretions
Tachycardia, hypertension
Usually manageable with:
Sedation
Anticholinergics
(La Via et al., 2022; Binsaeedu et al., 2023)
Clinical takeaway
Ketamine is not a bronchodilator you reach for early—it is one you reach for when everything else is failing.
Its strongest roles:
RSI induction in asthmatics
Adjunct infusion in refractory, intubated patients
Adrenaline (Epinephrine) in Asthma:
Old Drug, New Role
Adrenaline was once the cornerstone of asthma therapy. Today, its role is far more selective.
Mechanism
β₂ → bronchodilation
α₁ → reduces airway edema
β₁ → increases cardiac output
(Baggott et al., 2021; Mclean-Tooke et al., 2003)
Effectiveness vs β₂-agonists
Modern evidence shows:
Adrenaline is not superior to inhaled β₂-agonists.
Equivalent efficacy
No reduction in treatment failure
More cardiovascular side effects
(Baggott et al., 2021)
Current role: Not routine
Adrenaline should not be used routinely in asthma exacerbations.
Selective β₂-agonists (e.g., salbutamol) are:
Safer
Equally effective
(Indinnimeo et al., 2018)
When should you use adrenaline?
1. Asthma or Anaphylaxis (critical indication)
Adrenaline is first-line therapy here.
Treats bronchospasm
Reduces airway edema
Prevents cardiovascular collapse
(Cardona et al., 2020; Ring et al., 2018)
2. Severe, refractory asthma (rescue use)
Consider when:
Inhaled therapy is ineffective or not feasible
Patient is deteriorating rapidly
Dosing
IM adrenaline:
0.3–0.5 mg (1:1000)
Repeat every 20 minutes (max 3 doses)
SC terbutaline alternative:
0.25 mg every 20 minutes (max 0.75 mg)
(McFarlin et al., 2026; Leung, 2021)
Emerging data:
Recent RCT suggests low-dose SC adrenaline may improve airflow and oxygenation when added to standard therapy
(Gong et al., 2024)
Cautions
Tachy-arrhythmias
Hypertension
Myocardial ischemia (rare but relevant in older patients)
Clinical takeaway
Adrenaline is no longer a first-line bronchodilator—it is a situational drug.
Use it when:
There is anaphylaxis
Or severe asthma where inhaled therapy cannot be delivered effectively
Integrated Clinical Insight
Ketamine and adrenaline share a similar theme:
Both are powerful drugs—but neither belongs in routine asthma care.
They are:
Not first-line
Not substitutes for proper broncho-dilation
Not replacements for steroids
They are:
Bridging therapies in extreme physiology
In asthma, the right drug at the wrong time is as dangerous as the wrong drug.
Magnesium Sulfate: Selective but Effective
Dose:
2 g IV over 20–30 minutes
Mechanism:
Smooth muscle relaxation
Calcium antagonism
Evidence:
Improves lung function
Reduces hospitalisation in severe exacerbations
Magnesium is not a routine drug—it is a severity marker.
Use when:
Persistent severe obstruction after initial therapy
(Cahill et al., 2025; McFarlin et al., 2026)
Non-Invasive Ventilation (NIV): A Narrow Window
NIV can:
Reduce work of breathing
Improve ventilation
Delay or prevent intubation
But only in the right patient:
Awake and cooperative
Hemodynamically stable
No impending arrest
Typical starting settings:
IPAP: ~8 cm H₂O
EPAP: ~3 cm H₂O
(McFarlin et al., 2026)
NIV is a bridge—not a rescue for the crashing patient.
Evidence remains limited; use cautiously (Mein & Ferrera, 2025).
Systemic Beta-Agonists: Rescue Only
Not routine—but lifesaving in specific contexts.
Indications:
Failure of inhaled therapy
Inability to effectively inhale
Terbutaline (SC):
0.25 mg every 20 minutes (max 0.75 mg)
(McFarlin et al., 2026)
If the drug cannot reach the airway, change the route.
What Not to Do (Evidence-Based De-adoption)
Modern asthma care is defined as much by what we avoid:
❌ Aminophylline / theophylline → toxicity without benefit
❌ Routine antibiotics → mostly viral triggers
❌ Aggressive IV fluids → worsens pulmonary mechanics
❌ Mucolytics / chest physiotherapy → no benefit
In asthma, unnecessary treatments are not neutral—they are harmful.
(Mein & Ferrera, 2025; Farkas, 2024)
The Crashing Asthmatic: The Intubation Trap
Intubation in asthma is high-risk.
It can:
Worsen hyperinflation
Cause hypotension
Precipitate cardiac arrest
The goal is not to intubate early—it is to intubate safely, when unavoidable.
When to Intubate
Altered mental status
Exhaustion
Rising CO₂
Refractory hypoxemia
Failure of maximal therapy
(Cahill et al., 2025)
Intubation Strategy: Physiology First
Induction:
Ketamine 1–2 mg/kg IV
Why?
Bronchodilator
Preserves hemodynamics
(McFarlin et al., 2026)
Tube:
Use larger ETT → reduces resistance
Ventilation Strategy: This Determines Survival
The ventilator can save—or kill—the patient.
Core principles:
Tidal volume: ~6 mL/kg IBW
Respiratory rate: 8–12/min
I:E ratio: ≥1:3
Low or minimal PEEP
Why?
To:
Maximise expiratory time
Reduce air trapping
Prevent barotrauma
(Mein & Ferrera, 2025; McFarlin et al., 2026)
Permissive Hypercapnia
Accept PaCO₂ 70–100 mmHg
Maintain pH ≥7.15
Trying to normalise CO₂ in asthma is a common and dangerous mistake.
Post-intubation Collapse: The Critical Pearl
If the patient becomes:
Hypotensive
Hypoxic
Think:
Dynamic hyperinflation (auto-PEEP)
Immediate action:
Disconnect ventilator
Allow full exhalation
This can rapidly restore hemodynamics (Mein & Ferrera, 2025).
Beyond the ED:
The Next 7 Days Matter More Than the Next 7 Minutes
An exacerbation is a risk marker for future deterioration.
Discharge Essentials
Every patient should leave with:
Systemic steroids (5–7 days)
ICS-based controller therapy
Early follow-up (2–7 days)
(Cahill et al., 2025; GINA, 2025)
🔄 The Big Shift: ICS-Based Reliever Therapy
SABA-only therapy is obsolete.
Preferred strategy (GINA 2025):
ICS–formoterol as reliever (SMART/MART)
Benefits:
↓ exacerbations
↓ hospitalisations
↓ steroid exposure
(GINA, 2025)
The Most Underrated Intervention: Education
Correct inhaler technique
Provide written action plan
Address triggers and comorbidities
The best way to treat asthma in the ED is to prevent the next visit.
🧠 Final Clinical Synthesis
Acute asthma is a disease of:
Airflow limitation
Time-sensitive escalation
Ventilatory mechanics
Recognise early. Escalate appropriately. Ventilate gently. Discharge intelligently.
Final Take-home
Asthma kills by air trapping—not hypoxia. Treat accordingly.
References (AMA Style)
Mein SA, Ferrera MC. Management of asthma and COPD exacerbations in adults in the ICU. Chest Crit Care. 2025;3(1):100107.
Cahill KN, Dixon AE, Zachrison KS. Acute exacerbations of asthma in adults: Emergency department and inpatient management. UpToDate. Updated September 2025.
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2025 update.
McFarlin A, Chan C, Winters M, et al. Asthma in adults. EM:RAP CorePendium. Updated February 2026.
Farkas J. Asthma. EMCrit Project. January 2024.
Helman A, Sommer L, Mal S. The crashing asthmatic: Recognition and management of life-threatening asthma. Emergency Medicine Cases. April 2024.
Morris MJ, Mosenifar Z. Asthma guidelines: Guidelines summary. Medscape. Updated March 2026.
Goyal S, Agrawal A. Ketamine in status asthmaticus: A review. Indian J Crit Care Med. 2013;17:154–161.
La Via L, Sanfilippo F, Cuttone G, et al. Use of ketamine in patients with refractory severe asthma exacerbations: systematic review. Eur J Clin Pharmacol. 2022;78:1613–1622.
Alshehri F, Aloqaily H, Enabi J, Nafisah S. Ketamine for adults with severe asthma exacerbation: systematic review and meta-analysis. J Med Law Public Health. 2022.
Ueoka M, Subia G, Hipp C, et al. Ketamine infusion for refractory status asthmaticus: a case series. Chest. 2021.
Heshmati F, Zeinali M, Noroozinia H, et al. Use of ketamine in severe status asthmaticus. Iran J Allergy Asthma Immunol. 2003;2:175–180.
Binsaeedu A, Prabakar D, Ashkar M, et al. Safety and efficacy of ketamine in acute asthma exacerbation. Cureus. 2023;15.
Xiao S, Zhou Y, Wang Q, Yang D. Ketamine attenuates airway inflammation via Nrf2 pathway. Drug Des Devel Ther. 2022;16:4411–4428.
Baggott C, Hardy J, Sparks J, et al. Epinephrine versus β₂-agonists in acute asthma: systematic review and meta-analysis. Thorax. 2021;77:563–572.
Indinnimeo L, Chiappini E, Del Giudice M, et al. Guideline on management of acute asthma attack in children. Ital J Pediatr. 2018;44.
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance. World Allergy Organ J. 2020;13.
Ring J, Klimek L, Worm M. Adrenaline in acute treatment of anaphylaxis. Dtsch Arztebl Int. 2018;115:528–534.
Gong W, Jiang J, Fan H. Low-dose adrenaline in severe asthma. Pharm Bioprocess. 2024;6:106–112.
Leung J. Acute asthma exacerbations management. Drugs Context. 2021;10.